82152 Martinsried, de
+46 (70) 41071-80
Orfadin® Oral Suspension approved in the US
Twenty years ago, before pharmacological treatment was available, fewer than one third of infants diagnosed with HT-1 before two months of age lived past their second birthday. Today, treatment with Orfadin as an adjunct to dietary restriction as well as early diagnosis have improved outcomes for HT-1 patients. Orfadin is approved in the US and several other countries for the treatment of patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine.
"The HT-1 patient journey - from early screening and diagnosis, to improved medical care associated with continuous higher survival rates - has driven Sobi's commitment to develop new strengths and formulations for Orfadin to continually meet the medical needs of HT-1 patients", says Michael Yeh, Vice President Medical Affairs.
Maintaining a strong patient-centric approach is central, and Sobi is continuously developing initiatives based on the expressed needs of patients, healthcare providers and healthcare professionals. As more countries introduce newborn screening for HT-1, infants are diagnosed earlier in life. Dosing is adjusted by weight and as babies grow month by month, their dose is adjusted continuously. The new oral suspension of Orfadin aims to facilitate administration, especially in paediatric use.
Sobi(TM) is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ Stockholm. More information is available on www.sobi.com.
 van Spronsen FJ, Thomasse Y, Smit GP, et al. Hepatology. 1994;20(5):1187-1191
 Orfadin EPAR: Product information 25/07/2013 Orfadin -EMEA/H/C/000555 -IB/0045
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.